|
Canada-0-PATIO ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- Targeting ALK Rearrangements in NSCLC: Current State of the . . .
Currently, six ALK-target agents have been approved to treat advanced ALK+ NSCLC, including crizotinib, alectinib, ceritinib, ensartinib, brigatinib, and lorlatinib These targeted agents induce durable responses and improve survival outcomes Treatment with ALK inhibitors is recognized as the standard of care for advanced ALK+ NSCLC
- Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
- FDA Approves Alectinib for ALK-Positive Lung Cancer
Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
- FDA approves alectinib as adjuvant treatment for ALK-positive . . .
On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc ) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK
- ALK+ NSCLC Treatment Guidelines
Use of ALK TKIs is effective for treatment of patients with ALK+ NSCLC and CNS involvement, and evidence supports alectinib, brigatinib or ceritinib in this setting as first-line therapy
- Novel Small Molecule Earns FDA Fast Track Designation in ALK+ . . .
The FDA has granted fast track designation to TRI-611, an investigational molecular glue degrader therapy, as a treatment for those with ALK-positive non–small cell lung cancer (NSCLC), according to a press release from the developer, TRIANA Biomedicines, Inc 1 Developers engineered TRI-611 as an orally available investigational agent that targets ALK fusion proteins among patients with
- Efficacy and Safety of Continuing Next-Generation ALK TKIs . . .
Background The treatment paradigm for patients with ALK fusion–positive (ALK+) advanced or metastatic non–small cell lung cancer (NSCLC) has evolved with development of successive generations of ALK tyrosine kinase inhibitors (TKIs) Historically, patients received first-generation ALK TKI crizotinib as initial therapy, and upon disease progression, transitioned to more potent, selective
- ALK-Positive NSCLC Pipeline Gains Momentum as 6+ Pharma . . .
The treatment landscape for ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) is rapidly evolving, driven by continuous research and innovation from global pharmaceutical players DelveInsight’s latest report, “ ALK-positive Non-Small Cell Lung Cancer Pipeline Insight, 2026 ” highlights a steadily expanding pipeline supported by more than 6 key companies developing over 7 promising
- ALK-positive lung cancer: what it means and targeted . . .
What does ALK-positive in non-small cell lung cancer mean what are some treatment options? Georgetown University's Dr Stephen Liu shares insights
- TRIANA Biomedicines’ TRI-611 Granted U. S. FDA Fast Track . . .
The Phase 1 portion will consist of a dose escalation design, enrolling ALK+ NSCLC patients, who have been previously treated with standard of care ALK tyrosine kinase therapies The Phase 2 portion will further evaluate and characterize the efficacy and safety of TRI-611 across different patient cohorts
|
|